Outcome measurement
COMPLICATIONS, COMPLICATION
The primary endpoint of this phase I/II SPRDG clinical trial was the 30-day major complication rate. Any further prescribed drugs, laboratory or image examinations performed on patients and treatment courses were reviewed. Any complications requiring outpatient clinic attendance, rehospitalization, or unexpected hospital visits within 30 days were observed. Whether complications developed or not was confirmed through a weekly quality control meeting as previously described